Last updated: February 26, 2026
What Is the Drug Identified by NDC 49483-0619?
NDC 49483-0619 corresponds to Lenvatinib Mesylate, marketed under the brand Lenvima. Approved by the FDA in 2015, Lenvatinib is an oral kinase inhibitor used primarily for the treatment of differentiated thyroid carcinoma, advanced renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC).
Market Size and Growth Drivers
Global Market Overview
The global kinase inhibitor market was valued at approximately $15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 10% through 2027. The growth drivers include the rising incidence of cancer, expanding approval indications, and the increasing adoption of targeted therapies.
Indication-Specific Market
- Thyroid Cancer: Estimated 52,000 new cases diagnosed in the U.S. annually (SEER, 2022). The thyroid cancer segment accounts for a significant share of lenvatinib’s revenue.
- Renal Cell Carcinoma: Around 81,000 new RCC cases diagnosed yearly in the U.S. (SEER, 2022). Lenvatinib is often combined with other agents like everolimus for this indication.
- Hepatocellular Carcinoma: Approximately 42,000 new cases annually in the U.S. (SEER, 2022). Lenvatinib gained approval for HCC based on clinical trial data demonstrating non-inferiority to sorafenib.
Competitive Landscape
Main competitors include:
| Drug Name |
Market Share (2022) |
Year of Approval |
Indication(s) |
| Lenvatinib (Lenvima) |
35% |
2015 |
Thyroid, RCC, HCC |
| Sorafenib (Nexavar) |
30% |
2005 |
HCC, Thyroid (off-label) |
| Pazopanib (Votrient) |
8% |
2009 |
RCC |
| Cabozantinib (Cabometyx) |
12% |
2016 |
RCC, HCC |
Lenvatinib maintains a leading position due to its broad approvals and efficacy profile.
Pricing Analysis
Historical Price Trends
- Launch Price (2015): Approx. $11,000 per month per patient (wholesale acquisition cost, WAC).
- Current Price (2023): Estimated at $9,000–$10,000 per month, driven by competition and biosimilar entry in other indications.
Price Adjustment Factors
- Indication expansion increases total market size, supporting price stabilization.
- Reimbursement policies influence net prices; payers often negotiate discounts.
- Biosimilar competition for other kinase inhibitors affects overall pricing dynamics. No biosimilars directly target lenvatinib yet.
Cost-Effectiveness Analysis
Based on recent pharmacoeconomic evaluations:
| Study Aspect |
Finding |
| Cost per quality-adjusted life year (QALY) |
Ranges from $80,000 to $120,000 (varies by indication) |
| Break-even point |
Typically 6–12 months, depending on indication and payer |
Regulatory and Policy Influences
- FDA approvals renew market exclusivities until at least 2030 for primary indications.
- Patent protections extend through 2028, with some secondary patents potentially longer.
- Pricing pressure from health authorities and insurance providers limits price increases.
Future Price Projections
| Year |
Estimated Monthly Price |
Assumptions |
| 2023 |
$9,500 |
Maintains current trends due to competition and negotiations |
| 2025 |
$8,500–$10,000 |
Slight decline expected as biosimilars or generics are considered or as competitive pressures intensify |
| 2030 |
$7,000–$9,000 |
Possible reductions if biosimilars or alternative therapies gain broader adoption |
Key Factors Impacting Future Prices:
- Introduction of biosimilars or generics for lenvatinib.
- Reimbursement reforms impacting drug pricing strategies.
- Market penetration of combination therapies reducing reliance on monotherapy.
Summary
Lenvatinib (NDC 49483-0619) remains a significant treatment option in multiple cancers with an annual global market estimated at $4–5 billion. The U.S. market dominates with high drug prices around $9,000–$10,000 per month. Pricing is constrained by patent protections, payer negotiations, and emerging biosimilars. Price stability is likely into 2025 with gradual declines anticipated by 2030.
Key Takeaways
- Lenvatinib’s global market is driven by expanding indications and competing therapies.
- The current U.S. wholesale price ranges between $9,000 and $10,000 monthly.
- Patent expirations and biosimilar developments could reduce prices in the next five years.
- Cost-effectiveness analyses support sustained usage within established pricing frameworks.
- Reimbursement policies significantly influence net pricing and market penetration.
FAQs
1. What are the primary indications for lenvatinib?
Thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.
2. How does the price of lenvatinib compare to its competitors?
It is generally higher than older therapies like sorafenib but remains competitive due to multiple approvals and efficacy.
3. What factors could lead to price reductions in the future?
Introduction of biosimilars, patent expirations, shifts in reimbursement policies, and increased competition.
4. How does biosimilar entry affect the market?
Biosimilars tend to reduce prices through competition but have limited impact unless they gain regulatory approval for lenvatinib.
5. What are the key drivers of market growth through 2027?
Increasing prevalence of cancers treated by lenvatinib, ongoing indication approvals, and broader adoption of targeted therapies.
References
- SEER Cancer Stat Facts: Thyroid Cancer. National Cancer Institute. (2022).
- SEER Cancer Stat Facts: Kidney and Renal Pelvis Cancer. National Cancer Institute. (2022).
- SEER Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute. (2022).
- MarketWatch. (2023). Kinase Inhibitors Market Report.
